CytomX Therapeutics (CTMX) Income from Continuing Operations (2014 - 2026)
CytomX Therapeutics (CTMX) posted Income from Continuing Operations of 18248000.0 for Q1 2026, up 19.52% on a QoQ basis from 22674000.0 in Q4 2025, and down 177.57% year-over-year from 23525000.0 in Q1 2025.
CytomX Therapeutics (CTMX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 18248000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 177.57% year-over-year to 18248000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55305000.0 (down 232.94% YoY) and the FY2025 annual result came in at 13532000.0, down 142.46% from the prior year.
- Income from Continuing Operations was 18248000.0 for Q1 2026 at CytomX Therapeutics, up from 22674000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 23525000.0 in Q1 2025 and bottomed at 31981000.0 in Q1 2022.
- A 5-year average of 5870352.94 and a median of 3311000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 2155.2% in 2024, while the deepest fall reached 501.1% in 2024.
- CytomX Therapeutics' Income from Continuing Operations stood at 8775000.0 in 2022, then surged by 109.54% to 837000.0 in 2023, then soared by 2155.2% to 18876000.0 in 2024, then sank by 220.12% to 22674000.0 in 2025, then gained by 19.52% to 18248000.0 in 2026.
- Business Quant data shows CTMX's Income from Continuing Operations at 18248000.0 in Q1 2026, 22674000.0 in Q4 2025, and 14229000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | CytomX Therapeutics | 574.36 Mn | 227.66 Mn | - | -18.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.25 Mn |
| Dec 31, 2025 | -22.67 Mn |
| Sep 30, 2025 | -14.23 Mn |
| Jun 30, 2025 | -154,000.00 |
| Mar 31, 2025 | 23.53 Mn |
| Dec 31, 2024 | 18.88 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | -6.53 Mn |
| Mar 31, 2024 | 13.79 Mn |
| Dec 31, 2023 | 837,000.00 |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | -1.09 Mn |
| Mar 31, 2023 | -3.31 Mn |
| Dec 31, 2022 | -8.78 Mn |
| Sep 30, 2022 | -29.06 Mn |
| Jun 30, 2022 | -29.50 Mn |
| Mar 31, 2022 | -31.98 Mn |
| Dec 31, 2021 | -34.82 Mn |
| Sep 30, 2021 | -30.98 Mn |
| Jun 30, 2021 | -26.74 Mn |